글로벌 혈색소병 시장 – 2028년까지의 산업 동향 및 예측

혈색소병 시장의 시장 분석 및 통찰력

Data Bridge Market Research는 혈색소병 시장이 2021-2028년 예측 기간 동안 약 10.3%의 CAGR을 보일 것으로 분석했습니다. 전 세계적으로 혈색소병의 유병률이 증가하는 것은 혈색소병 시장 성장에 기인하는 주요 요인입니다.

헤모글로빈병은 적혈구에 직접 영향을 미치는 혈액 질환입니다. 헤모글로빈 분자의 글로빈 사슬 구조가 비정상적으로 나타나는 유전적 결함입니다. 낫적혈구 빈혈, 지중해 빈혈, 헤모글로빈 C 질환 및 헤모글로빈 SC 질환은 헤모글로빈병 질환의 가장 흔한 예입니다. 일반적으로 단일 유전자 질환에서 유전되며, 정기적인 적혈구(RBC) 수, 유전자 검사, 고성능 액체 크로마토그래피, 헤모글로빈 등전점 포커싱(Hb IEF), 헤모글로빈 전기영동(Hb ELP) 및 헤모글로빈 용해도 검사를 통해 검출됩니다.

헤모글로빈증에 대한 인식 증가는 시장 성장을 주도하는 요인 중 하나입니다. 헤모글로빈증에 대한 유리한 정부 계획, 정책 및 이니셔티브는 시장 성장률을 더욱 촉진할 것입니다. 빈혈과 같은 질병의 유병률 증가는 헤모글로빈증 시장의 성장을 촉진할 것입니다. 의료 인프라 개발에 대한 지출 증가와 개인 가처분 소득 증가는 간접적인 헤모글로빈증 치료 시장 성장 결정 요인으로 작용할 것입니다.

혈색소병에 사용되는 진단 대안의 가용성은 시장 성장에 큰 도전이 될 것입니다. 저소득 및 중산층 경제에서 적절한 진단 검사 장비가 부족하면 시장 성장률이 더욱 떨어질 것입니다.

This hemoglobinopathies market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on hemoglobinopathies market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Hemoglobinopathies Market Scope and Market Size

The hemoglobinopathies market is segmented on the basis of indication, end user, test type and pipeline therapeutics. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• Based on indication, hemoglobinopathies market is segmented into sickle cell disease, beta thalassemia and alpha thalassemia.
• On the basis of end user, the hemoglobinopathies market is segmented into hospitals, diagnostics laboratories and clinics.
• On the basis of test type, the hemoglobinopathies market is segmented into routine red blood cell (RBC) count, genetic testing, and haemoglobin by high performance liquid chromatography, haemoglobin isoelectric focusing (Hb IEF), haemoglobin electrophoresis (Hb ELP) and haemoglobin solubility test.
• Based on pipeline therapeutics, hemoglobinopathies market is segmented into niCord, ZFP transcription factors, ALN-TMP, drug targeting PRMT5 and drug targeting protein arginine methyltransferase 5.

Hemoglobinopathies Market Country Level Analysis

The hemoglobinopathies market is analysed and market size insights and trends are provided by country, indication, end user, test type and pipeline therapeutics as referenced above.

The countries covered in the hemoglobinopathies market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the hemoglobinopathies market and will continue to during the forecast period. This is because of the prevalence of a favourable reimbursement scenario and presence of major key players. Asia-Pacific on the other hand is set to project the highest CAGR for the forecast period. This is because of the rising expenditure of healthcare infrastructure, rising investments for research and development activities and increased focus of the government to empower the market in this region.

The country section of the hemoglobinopathies market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

Hemoglobinopathies market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for digital health technologies market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the hemoglobinopathies market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Hemoglobinopathies Market Share Analysis

The hemoglobinopathies market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to hemoglobinopathies market.

혈색소병 시장 보고서에 포함된 주요 기업으로는 Alnylam Pharmaceuticals, Inc., Gamida Cell, Biogen, Acceleron Pharma, Inc., Sangamo Therapeutics, Global Blood Therapeutics, Inc., Genetix Biotech Asia Pvt. Ltd., Prolong Pharmaceuticals, LLC., Emmaus Life Sciences, Inc., CELGENE CORPORATION, Abbott, Bio-Rad Laboratories, Inc., Danaher, Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Nexcelom Bioscience LLC, Bristol-Myers Squibb Company, Sysmex Corporation, Novartis AG, Medunik USA Inc., Optinova 등이 있습니다. 시장 점유율 데이터는 글로벌, 북미, 유럽, 아시아 태평양(APAC), 중동 및 아프리카(MEA), 남미에 대해 각각 제공됩니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁자에 대한 경쟁 분석을 개별적으로 제공합니다.

SKU-40589